Q-linea is making progress, including successful tenders, commercial evaluations, study support and partner discussions for the US market. The actual reported Q4 sales reflects the slow sales conversion process and the OPEX is high ahead of the next round of savings. The Italian market continues to be the most active market followed by France and Germany. Q-linea is also at the final stage of an FDA approval.

Read more and download the Research Update.
 
Follow companies at Redeye to receive the latest equity research within Life Science and Technology.
 
This is a press release from Redeye - Research Powered Investment Banking. www.redeye.se/